COLUCID PHARMACEUTICALS, INC. Financial Statements (2025 and earlier)
Company Profile
| Business Address |
222 THIRD STREET CAMBRIDGE, MA 02142 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2016 MRQ | 12/31/2015 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 64,508,141 | |||
| Cash and cash equivalents | 27,977,645 | |||
| Short-term investments | 36,530,496 | |||
| Prepaid expense | 808,608 | |||
| Total current assets: | 65,316,749 | |||
| Noncurrent Assets | ||||
| Other noncurrent assets | 21,190 | |||
| Total noncurrent assets: | 21,190 | |||
| TOTAL ASSETS: | 65,337,939 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 5,429,554 | |||
| Accounts payable | 1,649,398 | |||
| Accrued liabilities | 3,780,156 | |||
| Total current liabilities: | 5,429,554 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 1,500,000 | |||
| Deferred revenue and credits | 1,500,000 | |||
| Total noncurrent liabilities: | 1,500,000 | |||
| Total liabilities: | 6,929,554 | |||
| Equity | ||||
| Equity, attributable to parent | 58,408,385 | |||
| Common stock | 15,274 | |||
| Additional paid in capital | 145,531,670 | |||
| Accumulated other comprehensive loss | (43,279) | |||
| Accumulated deficit | (87,095,280) | |||
| Total equity: | 58,408,385 | |||
| TOTAL LIABILITIES AND EQUITY: | 65,337,939 | |||
Income Statement (P&L) (USD)
| 9/30/2016 TTM | 12/31/2015 | ||
|---|---|---|---|
| Operating expenses | (30,881,769) | ||
| Operating loss: | (30,881,769) | ||
| Nonoperating income (Investment Income, Nonoperating) | 142,240 | ||
| Loss from continuing operations: | (30,739,529) | ||
| Loss before gain (loss) on sale of properties: | (30,739,529) | ||
| Net loss attributable to parent: | (30,739,529) | ||
| Preferred stock dividends and other adjustments | (12,552,830) | ||
| Net loss available to common stockholders, basic: | (43,292,359) | ||
| Other undisclosed net income available to common stockholders, diluted | 4,798,194 | ||
| Net loss available to common stockholders, diluted: | (38,494,165) | ||
Comprehensive Income (USD)
| 9/30/2016 TTM | 12/31/2015 | ||
|---|---|---|---|
| Net loss: | (30,739,529) | ||
| Other comprehensive loss | (43,279) | ||
| Comprehensive loss, net of tax, attributable to parent: | (30,782,808) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.